Advances in pathophysiological understanding and the elucidation of a type 2 inflammatory
signature with interleukins 4, 5 and 13 at its center have led to the development of targeted …

Background: The prevalence of clinical asthma remission with biologics in severe asthma
has not been well understood yet. We do not even know whether there might be …

Background Mepolizumab (MEP) has been recently introduced to treat severe eosinophilic
asthma. Trials have demonstrated a significant effectiveness in this asthma phenotype. We …

Severe asthma is an important topic in respiratory diseases, due to its high impact on
morbidity and mortality as well as on health-care resources. The many challenges that still …

OBJECTIVE: Long-term efficacy of Benralizumab in real life is not clearly known. We
assessed the long-term effectiveness persistence to anti-IL-5R treatment in a group of …

Abstract Background Omalizumab, an anti-IgE antibody, has been widely used in many
countries, including Japan. However, some patients do not respond to omalizumab, and the …

Background: It is not clear whether mepolizumab is differently effective in allergic and
nonallergic severe eosinophilic asthmatics (SEA) in real life. Objective: We tested …

Objective This study analysed whether the persistence of both reversible airway obstruction
(RAO) and elevated BE counts was associated to reduced asthma control and accelerated …

Background and aims: Severe asthma may require the prescription of one of the biologic
drugs currently available, using surrogate markers of airway inflammation (serum IgE levels …

This brief paper is intended to be a quick guide to prescribe biologics in severe asthma by
following Global Initiative for Asthma (GINA) guidelines but also considering the author's …